In consideration of all RVX shareholders and on behalf of the RVX forum from which the idea for this presentation began, we deliver to the company a collective list of concerns of shareholders. In past webcasts by the company, we have been told that an effort would be made to keep us, the shareholders, better informed of the goings-on with the company. Although some progress has been made, much has been left untouched with respect to priority news items of investor interest, thus the following list was hatched.

1. Dart/City Loan: Please provide an update regarding plans for renegotiating continuation terms or replacing the Dart/City loan that is currently due for repayment around mid 2017. This is perhaps the most important concern amongst current shareholders and thus should be prioritized by management.

2. Improve the AGM: Make the AGM into a "shareholder summit", by webcasting the AGM, giving shareholders (both in Calgary and on the Webcast) ample time to ask questions and preparing more than a cursory presentation that mirrors everything we've seen before and repeatedly. Also, when is the anticipated date of the 2016 AGM?

3. Financial Update: Please review cash on hand, burn rate, and expected cash needs going forward over the next 3 years. Please include notation of changes in burn rate due to activities. Please cover in detail the additional funds that will need to be raised and approximately when those funds will be raised - including for the Citi/Dart loan mentioned previously.

4. Update on Business Arrangements: Please provide an overview of the types of partnerships, joint ventures, newco's or other business arrangements that the company is or will be having with pharma to move new molecules into the clinic. Please provide a status report of where those discussions are at currently (just beginning, well underway, close to fruition, etc.)

5. IP and Patent Protection: Resverlogix and Zenith each have very large compound libraries. Please review IP coverage for us including status of patents for RVX-208, ZEN-3694, ZEN-3717 and other lead/backup molecules and the lifetime of these patents. Are the vast compound libraries of Resverlogix and Zenith covered by patents at this time? Are there patents pending? Do new patents need to be filed? Many shareholders have legitimate concerns about patent protection after what happened with Zenith with their first lead molecule ZEN-3365 that was withdrawn due to potential IP conflict. We know that the term of the patents for 208 appears limited. Thus, we need to learn more about other patents. How does the synergy (or lack of synergy) of RVX-208 with rosuvastatin in BETonMACE affect patent protection and life of patent for RVX-208?

6. Licensing Deals: Update us in a detailed fashion about HepaLink and other licensing deal(s). What are their activities? When will the all-important revenue spigot be turned on? Do they have skin in the game? Are they paying for the Taiwan sites for BonM? What are the updates on the second licensing deal that we have been told at the Q1 and Q2 2016 updates that a second licensing deal was to be announced in 2016.

7. Update on Analyst Coverage: The most recent 2016 milestone checklist in the Q2 update indicated that 3 new analyst coverage programs were to be added in 2016. What is the status of these and when are the new analyst reports expected? Are any of the coverages provided by Marcel Wijma (Van Leeuwenhoeck Institute), John D. Vandermosten (Zacks Small Cap Research), or Stonegate Capital considered "new analyst coverage programs" or are other new analyst coverages expected in 2016?

8. Nasdaq listing: Please update on projected timeline and circumstances for a Nasdaq listing.

9. Long range plans: Resverlogix and Zenith each have very large compound libraries, which have the potential to give rise to numerous licensing deals, sale of IP, or spin offs. In past AGMs, it has been suggested that this large compound library may give rise to future spin-offs for different indications or classes of molecules, kind of like a "Star Factory." Please provide an overview of the long range plan for Resverlogix (and Zenith if applicable). If future spin-offs (Star Factories) do happen, what defines an individual "Star"? Is a Star a single molecule, a sub-family of related compounds from their big library, a BET inhibitor scaffold, a disease target, etc. What would actually be spun off as an independent entity?

10. New molecules and new indications: Give us more detail on the backup molecules for each company - and how and when they will be moved forward into the clinic. I say molecules, not molecule, as there is no need for any "Star Factory" to stop at only one backup molecule. Is Resverlogix pursuing the autoimmune molecule RVX-297, or another follow on molecule, for autoimmune indications such as rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis, Sjogren’s syndrome, and lupus? Or has the autoimmune program being pursued by Zenith and not Resverlogix? Is Resverlogix still on track to confirm an RVX-208 follow on candidate in 2016? Will this be for similar indications as for RVX-208 or for different indication(s)? At the Q1 update, it was stated that several follow on molecules have gone through various animal studies for different indication. At the NYAS symposium, it was indicated that other applications of RVX-208 may include muscular dystrophy and liver fibrosis. What other indications are being pursued? What are the plans for these indications? How will trials for new molecules and new indications be funded?

11. What distinguishes Resverlogix from Zenith?: Both companies command their own extensive BET inhibitor compound libraries. At the time Zenith was formed in 2013, it seemed that apoAI modulation defined Resverlogix and Zenith got everything else licensed to it from Resverlogix. But Zenith terminated this license on January 31, 2015 to pursue its own IP. What differentiates Zenith's compounds from Resverlogix's compounds? It would seem that Resverlogix and Zenith could each go after any disease they want. Although Zenith is currently going after oncology indications and Resverlogix is going after cardiovascular and renal, what is stopping Resverlogix and Zenith from directly competing for the same indications? Both companies have substantial overlap in Senior Management and Board of Directors. Please provide a better idea of what differentiates Resverlogix from Zenith currently and in the future.

12. Update on BETonMACE enrollment and study sites: Are all of the planned BETonMACE study sites now active? If not, what is the timeline for their activation. At the Q2 update we were told that Taiwan BETonMACE involvement should be launching by end of 2016. Will there be any other China study sites involved in BETonMACE? It was also mentioned in a past update that Australia was a possible BETonMACE site for more patients if needed. Is there any update on this, or is it still too early to know. Is the 125 MACE event futility analysis still on track for mid-2017?

13. Update on US sites in BETonMACE: At the Q2 update, we were told that by end of 2016 Resverlogix will have a Type C meeting with the FDA to discuss adding BETonMACE centers in US and review any outstanding requests from the FDA. We were told that "At the time of this meeting safety data from over 1,000 patients in the BETonMACE trial will be available, additional dose response work, MOA and liver biology work will be complete." Assuming that this meeting goes well, when is the earliest that US sites could be actively recruiting and how does this affect the original BETonMACE timeline? Resverlogix will also have a Type C meeting with the FDA by years end to discuss toxicology issues and go forward carcinogenicity program. Is there any update on the immunotoxicity rat study that was requested by the FDA? What concerns, if any, are there about the current BETonMACE protocol meeting FDA expectations?

14. Status of Orphan Indication Trials: Which orphan indications are going to be moved forward and when? What is the timeline and estimated launch date of the RVX-208 Phase 2 PNH trial? Is a H2 2016 trial start still a possibility? At the Q1 webcast, we were told that a PNH trial consisting of 30-40 patients as an estimated cost of 2-3 MM is still planned to launch in 2016. Is this still the case? Are there other complement disease trials being planned? How will these orphan trial(s) be funded?

15. Update on renal program: At the Q2 update we were told that by the end of 2016 that Resverlogix will have a Type B meeting with the FDA, pre IND for the new renal program, to review of top line PK data of the Phase 1 trial. Assuming that the Phase 1 New Zealand pharmacokinetic trial and FDA meeting go well, what is the plan and timeline for Phase 2/3 renal trial(s) going forward. BETonRENAL was mentioned at the Q2 update. Will this be a Phase 2 or Phase 3? How will these future BETonRENAL trial(s) be funded?

16. Update on Blood Bank and SomaScan Analysis: The analysis of blood samples with the SomaScan (SomaLogic, Boulder, CO) has been emphasized during recent scientific presentations such as the NYAS webcast. What new exciting insights has Resverlogix obtained from this data and how does Resverlogix plan to use this data going forward? Will this data be published?

17. Update on manuscripts: The 2016 milestone checklist most recently shown at the Q2 update indicated that 4 manuscripts were to be published in 2016. In addition to the January Atherosclerosis article and the May Metabolism article, what other peer-review publications are in the works or planned?

We, as a group of shareholders representing collectively what could be considered a somewhat significant retail share block , are intending to make the practice of forwarding to you the company, on a semi-annual basis, a list of our concerns that we would appreciate having addressed in upcoming webcasts, news releases, blog updates, quarterlies, or any other form of media you choose to go with. We of course look forward to hearing back from the Investor Relations Dept. or from our CEO himself, Don McCaffrey about our many concerns.